Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B
A male hepatitis B virus (HBV) carrier in his 40s under hemodialysis treatment exhibited chronic hepatitis (alanine aminotransferase: 41 IU/L, HBV-DNA: >9.1 log copies/mL). Following discontinuation of the initial treatment with pegylated interferon-α-2a at 24 weeks due to adverse effects, the ad...
Gespeichert in:
| Veröffentlicht in: | Case Reports in Nephrology and Dialysis 2020-09, Vol.10 (3), p.130-138 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 138 |
|---|---|
| container_issue | 3 |
| container_start_page | 130 |
| container_title | Case Reports in Nephrology and Dialysis |
| container_volume | 10 |
| creator | Aomura, Daiki Tachibana, Naoki Komatsu, Michiharu Kobayashi, Masakazu |
| description | A male hepatitis B virus (HBV) carrier in his 40s under hemodialysis treatment exhibited chronic hepatitis (alanine aminotransferase: 41 IU/L, HBV-DNA: >9.1 log copies/mL). Following discontinuation of the initial treatment with pegylated interferon-α-2a at 24 weeks due to adverse effects, the administration of tenofovirdisoproxil fumarate (TDF) (300 mg/week) led to a rapid improvement in hepatitis markers: HBV DNA became undetectable at month 34, and seroconversion of hepatitis B envelope antigen was confirmed at 45 months. No side effects were recorded during TDF treatment. TDF is a newly approved nucleoside analogue that may cause severe side effects via proximal tubular injury in patients with renal dysfunction. However, few reports have described its use in hemodialysis patients, whose anuric state may render them less susceptible to side effects including kidney injury. Hepatitis improved remarkably without any adverse drug reactions in the present case. TDF may therefore be considered for chronic hepatitis B patients receiving hemodialysis. |
| doi_str_mv | 10.1159/000508806 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_karge</sourceid><recordid>TN_cdi_karger_primary_508806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A647675613</galeid><doaj_id>oai_doaj_org_article_670283bf9c0d45d692b5c6b9714b240d</doaj_id><sourcerecordid>A647675613</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-7a9370bb4559a093636cc57fefbda2f3fb740a520140c76ea6615122ee1b7b1e3</originalsourceid><addsrcrecordid>eNptks9rFDEUxwdRbKk9ePcQ6MnD1pdkkmwuQp3aH1BUpJ5Dfu5mnZ2MyWy1_71ppywWJIeE9z758L7wmuYthlOMmfwAAAyWS-AvmkNCJF9IAezlP--D5riUTcVwyyhn8Lo5oJQwTBgcNq7r4xCt7tF3X3b9VFAK6NYPKaS7mNF5LGnM6U_s0cVuq7OePIoD0ujKb5OLur8vsaBveop-mNDvOK1Rt86pGisx1vJU25_eNK-C7os_frqPmh8Xn2-7q8XN18vr7uxmYdulnBZCSyrAmJYxqUFSTrm1TAQfjNMk0GBEC5qRGgSs4F5zjmsM4j02wmBPj5rr2euS3qgxxzrxvUo6qsdCyiul8xRt7xUXQJbUBGnBtcxxSQyz3EiBW0NacNX1cXaNO7P1ztZ8WffPpM87Q1yrVbpToqopoVVw8iTI6dfOl0lt0i4PNb8iTAAQEJhV6nSmVrpOFYeQqszW4_w22jT4EGv9jLdVyzh-0L6fP9icSsk-7EfCoB4WQu0XorLvZvanziuf9-S-ffLfdvflfCbU6AL9C1zRupw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2570020715</pqid></control><display><type>article</type><title>Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Karger Open Access</source><creator>Aomura, Daiki ; Tachibana, Naoki ; Komatsu, Michiharu ; Kobayashi, Masakazu</creator><creatorcontrib>Aomura, Daiki ; Tachibana, Naoki ; Komatsu, Michiharu ; Kobayashi, Masakazu</creatorcontrib><description>A male hepatitis B virus (HBV) carrier in his 40s under hemodialysis treatment exhibited chronic hepatitis (alanine aminotransferase: 41 IU/L, HBV-DNA: >9.1 log copies/mL). Following discontinuation of the initial treatment with pegylated interferon-α-2a at 24 weeks due to adverse effects, the administration of tenofovirdisoproxil fumarate (TDF) (300 mg/week) led to a rapid improvement in hepatitis markers: HBV DNA became undetectable at month 34, and seroconversion of hepatitis B envelope antigen was confirmed at 45 months. No side effects were recorded during TDF treatment. TDF is a newly approved nucleoside analogue that may cause severe side effects via proximal tubular injury in patients with renal dysfunction. However, few reports have described its use in hemodialysis patients, whose anuric state may render them less susceptible to side effects including kidney injury. Hepatitis improved remarkably without any adverse drug reactions in the present case. TDF may therefore be considered for chronic hepatitis B patients receiving hemodialysis.</description><identifier>ISSN: 2296-9705</identifier><identifier>EISSN: 2296-9705</identifier><identifier>DOI: 10.1159/000508806</identifier><identifier>PMID: 33251250</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Antigens ; Antiretroviral drugs ; Care and treatment ; Case Report ; Case reports ; Case studies ; chronic hepatitis b ; Chronic kidney failure ; Drug resistance ; Drug therapy ; end-stage renal disease ; Hemodialysis ; Hemodialysis patients ; Hepatitis ; Hepatitis B ; Infections ; Kidney diseases ; Liver cancer ; Mortality ; nucleoside analogue ; Patient outcomes ; Patients ; Serology ; Tenofovir ; tenofovirdisoproxil fumarate</subject><ispartof>Case Reports in Nephrology and Dialysis, 2020-09, Vol.10 (3), p.130-138</ispartof><rights>2020 The Author(s). Published by S. Karger AG, Basel</rights><rights>COPYRIGHT 2020 S. Karger AG</rights><rights>2020 The Author(s). Published by S. Karger AG, Basel . This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2020 by S. Karger AG, Basel 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c489t-7a9370bb4559a093636cc57fefbda2f3fb740a520140c76ea6615122ee1b7b1e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670323/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670323/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27612,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Aomura, Daiki</creatorcontrib><creatorcontrib>Tachibana, Naoki</creatorcontrib><creatorcontrib>Komatsu, Michiharu</creatorcontrib><creatorcontrib>Kobayashi, Masakazu</creatorcontrib><title>Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B</title><title>Case Reports in Nephrology and Dialysis</title><addtitle>Case Rep Nephrol Dial</addtitle><description>A male hepatitis B virus (HBV) carrier in his 40s under hemodialysis treatment exhibited chronic hepatitis (alanine aminotransferase: 41 IU/L, HBV-DNA: >9.1 log copies/mL). Following discontinuation of the initial treatment with pegylated interferon-α-2a at 24 weeks due to adverse effects, the administration of tenofovirdisoproxil fumarate (TDF) (300 mg/week) led to a rapid improvement in hepatitis markers: HBV DNA became undetectable at month 34, and seroconversion of hepatitis B envelope antigen was confirmed at 45 months. No side effects were recorded during TDF treatment. TDF is a newly approved nucleoside analogue that may cause severe side effects via proximal tubular injury in patients with renal dysfunction. However, few reports have described its use in hemodialysis patients, whose anuric state may render them less susceptible to side effects including kidney injury. Hepatitis improved remarkably without any adverse drug reactions in the present case. TDF may therefore be considered for chronic hepatitis B patients receiving hemodialysis.</description><subject>Antigens</subject><subject>Antiretroviral drugs</subject><subject>Care and treatment</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Case studies</subject><subject>chronic hepatitis b</subject><subject>Chronic kidney failure</subject><subject>Drug resistance</subject><subject>Drug therapy</subject><subject>end-stage renal disease</subject><subject>Hemodialysis</subject><subject>Hemodialysis patients</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Infections</subject><subject>Kidney diseases</subject><subject>Liver cancer</subject><subject>Mortality</subject><subject>nucleoside analogue</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Serology</subject><subject>Tenofovir</subject><subject>tenofovirdisoproxil fumarate</subject><issn>2296-9705</issn><issn>2296-9705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>DOA</sourceid><recordid>eNptks9rFDEUxwdRbKk9ePcQ6MnD1pdkkmwuQp3aH1BUpJ5Dfu5mnZ2MyWy1_71ppywWJIeE9z758L7wmuYthlOMmfwAAAyWS-AvmkNCJF9IAezlP--D5riUTcVwyyhn8Lo5oJQwTBgcNq7r4xCt7tF3X3b9VFAK6NYPKaS7mNF5LGnM6U_s0cVuq7OePIoD0ujKb5OLur8vsaBveop-mNDvOK1Rt86pGisx1vJU25_eNK-C7os_frqPmh8Xn2-7q8XN18vr7uxmYdulnBZCSyrAmJYxqUFSTrm1TAQfjNMk0GBEC5qRGgSs4F5zjmsM4j02wmBPj5rr2euS3qgxxzrxvUo6qsdCyiul8xRt7xUXQJbUBGnBtcxxSQyz3EiBW0NacNX1cXaNO7P1ztZ8WffPpM87Q1yrVbpToqopoVVw8iTI6dfOl0lt0i4PNb8iTAAQEJhV6nSmVrpOFYeQqszW4_w22jT4EGv9jLdVyzh-0L6fP9icSsk-7EfCoB4WQu0XorLvZvanziuf9-S-ffLfdvflfCbU6AL9C1zRupw</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Aomura, Daiki</creator><creator>Tachibana, Naoki</creator><creator>Komatsu, Michiharu</creator><creator>Kobayashi, Masakazu</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200901</creationdate><title>Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B</title><author>Aomura, Daiki ; Tachibana, Naoki ; Komatsu, Michiharu ; Kobayashi, Masakazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-7a9370bb4559a093636cc57fefbda2f3fb740a520140c76ea6615122ee1b7b1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antigens</topic><topic>Antiretroviral drugs</topic><topic>Care and treatment</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Case studies</topic><topic>chronic hepatitis b</topic><topic>Chronic kidney failure</topic><topic>Drug resistance</topic><topic>Drug therapy</topic><topic>end-stage renal disease</topic><topic>Hemodialysis</topic><topic>Hemodialysis patients</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Infections</topic><topic>Kidney diseases</topic><topic>Liver cancer</topic><topic>Mortality</topic><topic>nucleoside analogue</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Serology</topic><topic>Tenofovir</topic><topic>tenofovirdisoproxil fumarate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aomura, Daiki</creatorcontrib><creatorcontrib>Tachibana, Naoki</creatorcontrib><creatorcontrib>Komatsu, Michiharu</creatorcontrib><creatorcontrib>Kobayashi, Masakazu</creatorcontrib><collection>Karger Open Access</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case Reports in Nephrology and Dialysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aomura, Daiki</au><au>Tachibana, Naoki</au><au>Komatsu, Michiharu</au><au>Kobayashi, Masakazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B</atitle><jtitle>Case Reports in Nephrology and Dialysis</jtitle><addtitle>Case Rep Nephrol Dial</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>10</volume><issue>3</issue><spage>130</spage><epage>138</epage><pages>130-138</pages><issn>2296-9705</issn><eissn>2296-9705</eissn><abstract>A male hepatitis B virus (HBV) carrier in his 40s under hemodialysis treatment exhibited chronic hepatitis (alanine aminotransferase: 41 IU/L, HBV-DNA: >9.1 log copies/mL). Following discontinuation of the initial treatment with pegylated interferon-α-2a at 24 weeks due to adverse effects, the administration of tenofovirdisoproxil fumarate (TDF) (300 mg/week) led to a rapid improvement in hepatitis markers: HBV DNA became undetectable at month 34, and seroconversion of hepatitis B envelope antigen was confirmed at 45 months. No side effects were recorded during TDF treatment. TDF is a newly approved nucleoside analogue that may cause severe side effects via proximal tubular injury in patients with renal dysfunction. However, few reports have described its use in hemodialysis patients, whose anuric state may render them less susceptible to side effects including kidney injury. Hepatitis improved remarkably without any adverse drug reactions in the present case. TDF may therefore be considered for chronic hepatitis B patients receiving hemodialysis.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>33251250</pmid><doi>10.1159/000508806</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2296-9705 |
| ispartof | Case Reports in Nephrology and Dialysis, 2020-09, Vol.10 (3), p.130-138 |
| issn | 2296-9705 2296-9705 |
| language | eng |
| recordid | cdi_karger_primary_508806 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; Karger Open Access |
| subjects | Antigens Antiretroviral drugs Care and treatment Case Report Case reports Case studies chronic hepatitis b Chronic kidney failure Drug resistance Drug therapy end-stage renal disease Hemodialysis Hemodialysis patients Hepatitis Hepatitis B Infections Kidney diseases Liver cancer Mortality nucleoside analogue Patient outcomes Patients Serology Tenofovir tenofovirdisoproxil fumarate |
| title | Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T02%3A19%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Results%20of%20Tenofovir%20Disoproxil%20Fumarate%20in%20a%20Hemodialysis%20Patient%20with%20Chronic%20Hepatitis%20B&rft.jtitle=Case%20Reports%20in%20Nephrology%20and%20Dialysis&rft.au=Aomura,%20Daiki&rft.date=2020-09-01&rft.volume=10&rft.issue=3&rft.spage=130&rft.epage=138&rft.pages=130-138&rft.issn=2296-9705&rft.eissn=2296-9705&rft_id=info:doi/10.1159/000508806&rft_dat=%3Cgale_karge%3EA647675613%3C/gale_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2570020715&rft_id=info:pmid/33251250&rft_galeid=A647675613&rft_doaj_id=oai_doaj_org_article_670283bf9c0d45d692b5c6b9714b240d&rfr_iscdi=true |